Pioneering therapies and medications
Britannia Pharmaceuticals is dedicated to improving the lives of people with long-term neurological conditions, and providing important support for their families, caregivers, and medical teams.
We offer world-leading medications to improve disease management and quality-of-life for patients, as well as supporting treatment programmes for patients, families, and carers that provide extra assistance in managing these conditions.
We remain committed to making breakthroughs and providing high-quality treatments and services that improve the lives of people living with Parkinson’s disease, schizophrenia and other conditions, and provide support to everyone involved in their care.
Parkinson’s disease is a progressive neurodegenerative condition that occurs when some of the cells in the brain (neurons) stop working properly and are lost over time. People with Parkinson’s disease typically have movement-related (motor) problems like shaking, rigidity and difficulty walking.
Since 1982, Britannia has pioneered the development and marketing of products and services for the treatment of this condition.
Schizophrenia is a long-term severe mental health condition that causes a range of psychological symptoms. It is often described as a type of psychosis where people are not always able to distinguish thoughts and ideas from reality.
Since 2004, Britannia has pioneered the development and marketing of products and services for the treatment of this disorder.